Collaborations

Collaborations

XNK Therapeutics has actively participated in several public-private partnerships to develop its technology platform. The main collaborating partners have been Karolinska Institutet, Karolinska University Hospital, and the Royal Institute of Technology.

XNK Therapeutics is currently participating in three public-private partnerships. They have allowed the company to develop its technology within the competence center AdBIOPRO, as well as its business model within the SWElife-ATMP organization. The latest public-private partnership, the one with the competence center NextGenNK, will allow XNK Therapeutics to build further on the clinical development of its leading investigational drug candidate, CellProtect. XNK Therapeutics is always open for, and actively looking, collaboration partners.

Please contact our CEO Johan Liwing (johan.liwing@xnktherapeutics.com) for discussing research collaborative ideas.


 

NextGenNK is Competence Center initiated by Sweden’s innovation agency (Vinnova). It was launched in 2020 for the development of next-generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. XNK Therapeutics is a Partner within this Competence Center. Within this collaboration, one mission is to perform an open, randomized, controlled phase II trial with CellProtect in combination with a monoclonal antibody in patients with Multiple myeloma.

 

The Competence Centre for Advanced BioProduction by Continuous Processing, AdBIOPRO, aims at developing competitive technology for bioproduction, focusing on the imminent paradigm shift towards continuous processes of biopharmaceuticals and on the manufacturing of emerging potent therapeutic products such as recombinant viral vector and cell products. XNK Therapeutics is a Partner within the Competence Center with the aim to establish an outscaled manufacturing protocol enabling the production of CellProtect in Sweden to support clinical studies. The work addresses biological factors governing a product of high quality.

 

Swelife-ATMP is a project within the strategic innovation program Swelife, funded by Sweden’s innovation agency (Vinnova) and the Swedish Energy Agency. The aim of the project is the development of the knowledge, processes, competencies, and support functions required to take an ATMP from the preclinical stage to the patient. XNK Therapeutics focuses on business development for CellProtect based on health economics data, value-based health care, and pricing infrastructures. The aim is to identify opportunities and threats for CellProtect to reach the use in clinical practice for the benefits of the patients.